Voxvoganan

N/A

Report date: 2022/12/31 17:21:46
NME

Base Information

Drug NameVoxvoganan
Drug Alias NameLytixarLTX-9LTX-109
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Synthetic peptide
Mechanisms of ActionCell membrane modulators
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Dermatitis, AtopicHidradenitis Suppurativa +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenNorwayHungary +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLytix Biopharma As
China Registration ClassN/A

Develop Information

Active CompaniesPharma Holdings AS
Inactive CompaniesLytix Biopharma As
Active IndicationsHidradenitis SuppurativaStaphylococcal Infections
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Dermatitis, AtopicImpetigo +[4] 

Other Information

ATC CodeN/A
Related LinksN/A